🚀 VC round data is live in beta, check it out!
Grape King Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Grape King Bio and similar public comparables like Medy-Tox, Zhejiang Shouxiangu, Scitop Bio-tech, Aarti Pharmalabs and more.
Grape King Bio Overview
About Grape King Bio
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicine, liquid tonic, drink, and healthy food. The company has three segments: MLM (Multi-Level Marketing) is a direct seller of Pro-partner Inc, including the company’s development and manufacturing products for Pro-partner Inc, Distributors segment includes the company’s self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
Founded
1969
HQ
Employees
565
Website
Financials (LTM)
EV
$470M
Grape King Bio Financials
Grape King Bio reported last 12-month revenue of $328M.
In the same LTM period, Grape King Bio generated $39M in net income.
Revenue (LTM)
Grape King Bio P&L
In the most recent fiscal year, Grape King Bio reported revenue of $323M and EBITDA of $89M.
Grape King Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $328M | XXX | $323M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $240M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 75% | XXX | XXX | XXX |
| EBITDA | — | XXX | $89M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $39M | XXX | $38M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Grape King Bio Stock Performance
Grape King Bio has current market cap of $564M, and enterprise value of $470M.
Market Cap Evolution
Grape King Bio's stock price is $3.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $470M | $564M | -0.5% | XXX | XXX | XXX | $0.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGrape King Bio Valuation Multiples
Grape King Bio trades at 1.4x EV/Revenue multiple, and 5.3x EV/EBITDA.
EV / Revenue (LTM)
Grape King Bio Financial Valuation Multiples
As of March 21, 2026, Grape King Bio has market cap of $564M and EV of $470M.
Equity research analysts estimate Grape King Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grape King Bio has a P/E ratio of 14.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $564M | XXX | $564M | XXX | XXX | XXX |
| EV (current) | $470M | XXX | $470M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBIT | 6.8x | XXX | 7.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.0x | XXX | XXX | XXX |
| P/E | 14.4x | XXX | 14.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Grape King Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Grape King Bio Margins & Growth Rates
Grape King Bio's revenue in the last 12 month grew by 6%.
Grape King Bio's revenue per employee in the last FY averaged $0.6M.
Grape King Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (10%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Grape King Bio Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Shouxiangu | XXX | XXX | XXX | XXX | XXX | XXX |
| Scitop Bio-tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grape King Bio M&A Activity
Grape King Bio acquired XXX companies to date.
Last acquisition by Grape King Bio was on XXXXXXXX, XXXXX. Grape King Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Grape King Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGrape King Bio Investment Activity
Grape King Bio invested in XXX companies to date.
Grape King Bio made its latest investment on XXXXXXXX, XXXXX. Grape King Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Grape King Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Grape King Bio
| When was Grape King Bio founded? | Grape King Bio was founded in 1969. |
| Where is Grape King Bio headquartered? | Grape King Bio is headquartered in Taiwan. |
| How many employees does Grape King Bio have? | As of today, Grape King Bio has over 565 employees. |
| Is Grape King Bio publicly listed? | Yes, Grape King Bio is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Grape King Bio? | Grape King Bio trades under 1707 ticker. |
| When did Grape King Bio go public? | Grape King Bio went public in 1982. |
| Who are competitors of Grape King Bio? | Grape King Bio main competitors are Medy-Tox, Zhejiang Shouxiangu, Scitop Bio-tech, Aarti Pharmalabs. |
| What is the current market cap of Grape King Bio? | Grape King Bio's current market cap is $564M. |
| What is the current revenue of Grape King Bio? | Grape King Bio's last 12 months revenue is $328M. |
| What is the current revenue growth of Grape King Bio? | Grape King Bio revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Grape King Bio? | Current revenue multiple of Grape King Bio is 1.4x. |
| Is Grape King Bio profitable? | Yes, Grape King Bio is net-income-positive (as of the last 12 months). |
| What is the current net income of Grape King Bio? | Grape King Bio's last 12 months net income is $39M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.